Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALTS ALT5 Sigma	$6.80 +3.5%	$7.45	$1.55 ▼ $10.95	$146.94M	2.17	1.56 million shs	17.96 million shs
CLSD Clearside Biomedical	$0.40 -1.8%	$0.61	$0.29 ▼ $1.65	$31.40M	2.08	1.84 million shs	690,819 shs
CLYM Climb Bio	$2.48 +4.2%	$1.50	$1.05 ▼ $8.79	$168.05M	-0.11	353,253 shs	1.05 million shs
CTOR Citius Oncology	$1.89 +8.0%	$2.46	$0.55 ▼ $6.19	$148.12M	3	1.27 million shs	378,730 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALTS ALT5 Sigma	0.00%	+10.61%	-7.20%	-26.26%	+158.66%
CLSD Clearside Biomedical	0.00%	-3.74%	-18.10%	-52.82%	-60.08%
CLYM Climb Bio	0.00%	+25.26%	+64.14%	+101.69%	+237,999,900.00%
CTOR Citius Oncology	0.00%	+3.55%	-11.17%	+92.31%	-6.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALTS ALT5 Sigma	0.5613 of 5 stars	0.0	4.0	2.8	0.0	0.0
CLSD Clearside Biomedical	1.8565 of 5 stars	4.1	3.0	0.6	0.0	0.0
CLYM Climb Bio	3.4065 of 5 stars	3.7	0.0	3.2	2.5	1.3
CTOR Citius Oncology	1.3509 of 5 stars	3.0	0.0	1.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALTS ALT5 Sigma	0.00	N/A	N/A	N/A
CLSD Clearside Biomedical	2.17	Hold	$4.20	950.00% Upside
CLYM Climb Bio	3.33	Buy	$9.00	262.90% Upside
CTOR Citius Oncology	2.00	Hold	$3.00	58.73% Upside

Current Analyst Ratings Breakdown

Latest CLSD, CTOR, CLYM, and ALTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	CLYM Climb Bio	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/15/2025	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
7/18/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
7/18/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/18/2025	CLSD Clearside Biomedical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/17/2025	CLSD Clearside Biomedical	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$3.00
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALTS ALT5 Sigma	$22.26M	6.60	N/A	N/A	$0.49 per share	13.88
CLSD Clearside Biomedical	$4.17M	7.54	N/A	N/A	($0.51) per share	-0.78
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.15 per share	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.64 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALTS ALT5 Sigma	-$6.24M	N/A	0.00	∞	N/A	-74.89%	-179.27%	-16.28%	N/A
CLSD Clearside Biomedical	-$34.35M	-$0.37	N/A	N/A	N/A	-665.19%	N/A	-124.15%	11/11/2025 (Estimated)
CLYM Climb Bio	-$73.90M	-$0.70	N/A	N/A	N/A	N/A	-23.10%	-22.47%	11/11/2025 (Estimated)
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-51.93%	-22.17%	N/A

Latest CLSD, CTOR, CLYM, and ALTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	CLYM Climb Bio	-$0.19	-$0.13	+$0.06	-$0.13	N/A	N/A
8/8/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	-$0.06	+$0.06	-$0.06	$0.50 million	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALTS ALT5 Sigma	$1.22	17.94%	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALTS ALT5 Sigma	1.45	0.88	0.88
CLSD Clearside Biomedical	N/A	3.87	3.87
CLYM Climb Bio	N/A	14.08	14.08
CTOR Citius Oncology	0.12	0.35	0.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALTS ALT5 Sigma	6.27%
CLSD Clearside Biomedical	18.75%
CLYM Climb Bio	69.76%
CTOR Citius Oncology	70.52%

Insider Ownership

Company	Insider Ownership
ALTS ALT5 Sigma	4.90%
CLSD Clearside Biomedical	6.70%
CLYM Climb Bio	3.20%
CTOR Citius Oncology	4.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALTS ALT5 Sigma	170	21.61 million	20.55 million	N/A
CLSD Clearside Biomedical	30	78.51 million	73.25 million	Optionable
CLYM Climb Bio	9	67.76 million	65.60 million	N/A
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A

CLSD, CTOR, CLYM, and ALTS Headlines

Recent News About These Companies

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

August 22 at 8:47 AM | prnewswire.com

Citius Oncology (NASDAQ:CTOR) Shares Up 3.6% - Time to Buy?

August 20, 2025 | marketbeat.com

Citius Oncology Conducts Public Offering of Stock

August 18, 2025 | tipranks.com

Citius Oncology (NASDAQ:CTOR) Releases Earnings Results

August 14, 2025 | marketbeat.com

Citius Oncology Beats Fiscal Q3 EPS

August 13, 2025 | theglobeandmail.com

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business ...

August 12, 2025 | gurufocus.com

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

August 12, 2025 | prnewswire.com

Citius Oncology (NASDAQ:CTOR) Upgraded to "Hold" at Wall Street Zen

July 26, 2025 | marketbeat.com

Citius Oncology Announces Closing of $9.0 Million Public Offering

July 17, 2025 | prnewswire.com

Citius Oncology Announces Pricing of $9.0 Million Public Offering

July 16, 2025 | prnewswire.com

Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution Network

July 15, 2025 | msn.com

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

July 15, 2025 | prnewswire.com

Citius Oncology launches $15M equity and warrant offering; shares down

July 15, 2025 | msn.com

Citius Oncology, Inc. Common Stock (CTOR) Financials

July 11, 2025 | nasdaq.com

Citius Oncology Regains Nasdaq Compliance June 2025

June 27, 2025 | tipranks.com

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

June 17, 2025 | prnewswire.com

Citius Oncology stock soars on distribution deal

June 9, 2025 | in.investing.com

Maxim Group Downgrades Citius Oncology (CTOR)

May 24, 2025 | msn.com

Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | prnewswire.com

Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future

May 7, 2025 | finance.yahoo.com

Citius Oncology, Inc. Common Stock (CTOR) Institutional Holdings

May 5, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CLSD, CTOR, CLYM, and ALTS Company Descriptions

ALT5 Sigma NASDAQ:ALTS

$6.80 +0.23 (+3.50%)

Closing price 04:00 PM Eastern

Extended Trading

$6.70 -0.10 (-1.47%)

As of 05:35 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Clearside Biomedical NASDAQ:CLSD

$0.40 -0.01 (-1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$0.42 +0.02 (+3.75%)

As of 05:24 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Climb Bio NASDAQ:CLYM

$2.48 +0.10 (+4.20%)

As of 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Citius Oncology NASDAQ:CTOR

$1.89 +0.14 (+8.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.84 -0.05 (-2.91%)

As of 05:27 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time